<DOC>
	<DOC>NCT00724776</DOC>
	<brief_summary>This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients</brief_summary>
	<brief_title>Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Have a clinical diagnosis of CHC established on the basis of a detectable viral load as measured by a serum HCV RNA test at least 6 months before and during the screening period. Age 20 to 69 years Have compensated liver disease results on screening laboratory assessment Evidence of decompensated liver disease and/or liver cirrhosis. Body weight &lt; 50 kg. A history of immunologically mediated disease. A history or other clinical evidence of interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Chronic hepatitis C, Albinterferon alfa 2b, phase I, Japan</keyword>
</DOC>